
    
      Part A ( for Healthy volunteers) of the study is completed

      Part B dose-escalation study is completed. Recruitment in dose-expansion is ongoing in India
      and Korea

      Part C study in subjects with treatment-refractory/intolerant is enrolling globally.
    
  